Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

Abstract Background Neuroblastoma is the most common extra-cranial solid tumor among children. Despite intensive treatment, patients with advanced disease mostly experience dismal outcomes. Here, we proposed the use of topotecan and cyclophosphamide containing induction regimen as an upfront therapy...

Full description

Bibliographic Details
Main Authors: Piya Rujkijyanont, Apichat Photia, Chanchai Traivaree, Chalinee Monsereenusorn, Usanarat Anurathapan, Panya Seksarn, Darintr Sosothikul, Piti Techavichit, Kleebsabai Sanpakit, Kamon Phuakpet, Surapon Wiangnon, Thirachit Chotsampancharoen, Su-on Chainansamit, Somjai Kanjanapongkul, Arunotai Meekaewkunchorn, Suradej Hongeng
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Cancer
Subjects:
High risked neuroblastoma
Topotecan
Induction therapy
Treatment response
Prognostic factor
Treatment-related toxicity
Online Access:http://link.springer.com/article/10.1186/s12885-019-6186-z

Internet

http://link.springer.com/article/10.1186/s12885-019-6186-z

Similar Items